EchoGo ® Amyloidosis is an AI-based software-only medical device, which aims to improve early detection of Cardiac Amyloidosis, an underdiagnosed cause of heart failure. EchoGo ® Amyloidosis sits on ...

We shared the full results from the pivotal HELIOS-B study at ESC in August and additional ... We then saw favorable impact on cardiac biomarkers as well as echocardiographic assessments ...

Cardiac amyloidosis is becoming increasingly recognized as an etiology ... (Click here for more results from HELIOS-B presented at ESC Congress 2024.) New therapeutic classes in the pipeline include ...

The European Society of Cardiology (ESC) Guidelines on cardiomyopathies ... Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein ...

Cardiac amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins. These amyloids can gather in different organs throughout the ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

REPLY: Thank you for your eagle-eyed attention to detail and for bringing the inconsistency to our attention regarding the SPECT reconstruction display between 2 articles published in the June 2023 ...

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood ...